Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Renal Clearance

Renal Clearance

The glomerular filtration rate (GFR) is a critical marker of kidney function, reflecting the efficiency of filtration by the glomeruli. Renal clearance of specific substances, such as inulin or creatinine, is commonly used to measure GFR.
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...

Factors Affecting Renal Clearance: Renal Impairment

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

International journal of cancer·2025

Same author

Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy.

World journal of urology·2025

Same author

Radical Prostatectomy Versus Radiotherapy for Prostate Cancer: Stage-, Age-, and Frailty-Specific Cancer-Control Outcomes of 2600 Patients.

Deutsches Arzteblatt international·2025

Same author

Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate Cancer.

Clinical genitourinary cancer·2025

Same author

Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

[Non-clear cell renal cell carcinoma].

Marit Ahrens¹, Lothar Bergmann^2,3

¹Medizinische Klinik II, Universitätsklinik, J.W. Goethe Universität, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland.

Urologie (Heidelberg, Germany)

|November 26, 2024

Summary

Treatment for rare non-clear cell renal cell carcinomas (nccRCC) lacks specific guidelines due to limited data. Current recommendations suggest treating nccRCC similarly to clear cell types, using targeted therapies or immunotherapies.

Keywords:

Immune checkpoint inhibitors Neoplasm metastasis Systemic treatment Tyrosine kinase inhibitors mTOR-inhibitors

More Related Videos

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Related Experiment Videos

Last Updated: Jun 6, 2025

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Area of Science:

Oncology
Nephrology

Context:

Non-clear cell renal cell carcinomas (nccRCC) represent a heterogeneous group of kidney cancers, comprising 20-25% of all renal tumors.
Numerous rare subtypes exist, each with unique histological and molecular characteristics, often representing less than 1% of cases.

Purpose:

To review current treatment recommendations for localized and advanced non-clear cell renal cell carcinomas.
To present data on systemic therapies utilized for nccRCC subtypes.
To highlight the need for entity-specific treatment guidelines and further research.

Summary:

Current treatment strategies for nccRCC are largely extrapolated from clear cell renal cell carcinoma (ccRCC) due to a lack of large-scale studies for rare subtypes.
Treatment options include monotherapies with tyrosine kinase inhibitors (TKIs) or mTOR inhibitors (for specific subtypes like chromophobe RCC), and combination therapies such as immune checkpoint inhibitor (ICI)/ICI or TKI/ICI.
Treatment decisions are guided by risk factors and individual patient considerations.

Impact:

The absence of entity-specific guidelines and randomized trials for nccRCC creates uncertainty in optimal treatment selection.
Standardizing treatment approaches similar to ccRCC is a current practice, but may not be universally optimal.
Urgent need for randomized clinical trials to establish evidence-based guidelines for rare nccRCC subtypes to improve patient outcomes.